Abstract | Mutations of the cardiac sodium channel (Na v 1.5) can induce gain or loss of channel function. Gain-of-function mutations can cause long QT syndrome type 3 and possibly atrial fibrillation, whereas loss-of-function mutations are associated with a variety of phenotypes, such as Brugada syndrome, cardiac conduction disease, sick sinus syndrome, and possibly dilated cardiomyopathy. The phenotypes produced by Na v 1.5 mutations vary according to the direct effect of the mutation on channel biophysics, but also with age, sex, body temperature, and between regions of the heart. This phenotypic variability makes genotype-phenotype correlations difficult. In this Perspectives article, we propose that phenotypic variability not ascribed to mutation-dependent changes in channel function might be the result of additional modifiers of channel behaviour, such as other genetic variation and alterations in transcription, RNA processing, translation, post-translational modifications, and protein degradation. Consideration of these modifiers might help to improve genotype-phenotype correlations and lead to new therapeutic strategies.
Introduction
A functional heart pumps blood throughout the body by regular, rhythmic contractions, which are controlled by electrical impulses usually initiated at specialized pacemaker sites and conducted throughout the heart, in part, by a myocardial conduction system. Under usual circumstances, the sinoatrial node, also known as the pacemaker, gener ates the initial depolarization that stimulates the atrial muscle to contract. The signal then travels to the atrioventricular node and con ducts through the bundle of His and bundle branches to the Purkinje fibres. These fibres articulate with the sub endocardial muscle, ensuring ventricular contraction from the apex to the base of the heart. This sequence of electrical activity can be monitored on the electrocardiogram (ECG).
The importance of the cardiac sodium channel (Na v 1.5) for cardiac electrical stabil ity is highlighted by lethal arrhythmias that arise as the result of inherited genetic defects in the Na v 1.5 channel. Alterations in cardiac Na v 1.5 have also been implicated in arrhythmic risk associated with acquired heart disease. 1, 2 The cardiac Na v 1.5 is responsible for the fast inward Na + current (I Na ) that initiates the depolarizing phase 0 of the cardiac action potential (Figure 1 ), except in the sinoatrial and atrio ventricular nodes. In addition to intercellular com munication via gap junctions, Na v 1.5 is a major determinant of impulse conduction velocity in cardiac tissues. 3 The biophysical properties of the sodium channel are complex. The α subunit of Na v 1.5, which is encoded by SCN5A, forms the ionconducting pore and changes its structural conformation on a timescale of milliseconds in response to alterations in membrane potential. This process is termed voltagedependent gating. 4 The α subunit is composed of an intracellular Nterminus and Cterminus, and four homologous domains (I-IV) that form a pore to conduct Na + ions across the cell membrane. 5 The four domains are attached to one another by cytoplasmic linker sequences with important residues for channel gating and posttranslational modi fications, such as phosphorylation. Each domain contains six transmembrane seg ments (S1-S6). The four positively charged S4 segments constitute the voltage sensor, responsible for increased channel permeabil ity during membrane depolarization. 6 The S5 and S6 segments of all four domains form the ionconducting pore, and the intercon necting Ploops make up the channel's selec tivity filter. 7, 8 The α subunit interacts with accessory proteins, including β subunits and other proteins, to form a macromolecular complex that modulates channel expression and f unction ( Figure 2 ). 9 Mutations in SCN5A produce a variety of clinical phenotypes. Some portion of pheno typic variability is the result of the direct effects of the mutations on the Na v 1.5 bio physical properties. These effects are often divided into gain or loss of channel function (that is, increased or decreased I Na , respec tively). In gainoffunction mutations, an increase in the persistent late I Na (I NaL ) during the action potential plateau, rather than in peak I Na , is generally thought to be respon sible for the phenotype. Gainoffunction mutations in SCN5A can result in longQT syndrome type 3 ( Figure 3 ). Conversely, lossoffunction mutations in SCN5A can lead to a decrease in peak I Na , resulting in phenotypes including Brugada syndrome (BrS), sick sinus syndrome, cardiac conduc tion diseases, and possibly dilated cardio myopathy. Some SCN5A mutations have also been shown to cause mixed phenotypes (overlap syndromes) or been linked with familial lone atrial fibrillation. Occasionally, mutations can cause both an increase in I NaL and a simultaneous reduction in peak I Na , thereby having both gainoffunction and lossoffunction properties.
The effects of mutations and their con tribution to phenotypic variability have been extensively studied and reviewed pre viously, [10] [11] [12] [13] [14] and so are not discussed further in this article. However, different SCN5A mutations can generate different clinical syndromes. These syndromes can manifest in a particular chamber or region of the heart. Additionally, the phenotype of a par ticular SCN5A mutation can show a variable p enetrance between individuals, and can vary within an individual as a result of factors such as age, time of day, and body tempera ture. The source of this phenotypic variation OPINION Cardiac sodium channel mutations: why so many phenotypes?
is uncertain, and this degree of variability makes genotype-phenotype correlations difficult. Furthermore, the lack of correla tion complicates medical decisionmaking in patients with known mutations.
In this Perspectives article, we propose that phenotypic variability not ascribed to mutationdependent changes in channel biophysics might be the result of additional modifiers of channel behaviour. Established modifiers include additional genetic variants in the SCN5A gene. Other potential modi fiers include alterations in the expression or function of the mutated channel (intrinsic modifiers), or changes in the expression of other channels or genes that can modify the overall electrical effect of an SCN5A muta tion (extrinsic modifiers). Consideration of these modifiers might help to improve genotype-phenotype c orrelations and lead to new therapeutic strategies.
Phenotypic variability
The clinical phenotypic penetrance and manifestation of an SCN5A mutation can vary with sex, the presence of genetic modifiers, circadian rhythm, and ageing ( Figure 4 ). For example, in patients with long QT syndrome type 3, men tend to have a longer corrected QT interval than women (Figure 4a ). 15 Furthermore, BrS affects far more men than women. [16] [17] [18] Sex can influence the clinical phenotype of an individual mutation. For example, within a single family, four male members carry ing a lossoffunction mutation in SCN5A (G1406R) had BrS, whereas seven other family mem bers (six of whom were women) carry ing the same mutation had cardiac con duction disease. 17 The mechanism of this sexdependent effect is still uncertain. Sex hor mones, such as 5dihydrotestosterone , oestrogen, and progesterone, might cause differences in QT intervals and gene expression of cardiac ion channels. 19 For female patients, hormonal changes owing to menses and pregnancy might induce QT prolongation and increase susceptibility to arrhythmias. 20 The phenotype of SCN5A mutations can be agedependent. For example, despite carry ing the mutation since birth, patients with BrS do not typically develop an arrhythmic phenotype until aged approxi mately 34-53 years. 21 Interestingly, the male predominance of an arrhythmic phenotype is not observed in children with BrS. 22 Age dependent hormonal changes have been proposed to explain the increased risk of spontaneous arrhythmias in men after puberty. 22, 23 Moreover, within an individual patient with an SCN5A mutation associated with BrS, phenotypic variability exists in the ECG manifestations of the disease as a func tion of time. A patient with BrS can show circadian changes in ECG patterns and sus ceptibility to lethal ventricular fibrillation (Figure 4c ), and ECG manifestations can worsen with fever. 24 Furthermore, cardiac conduction diseases can be progressive and worsen with age ( Figure 4d ). 25 
Intrinsic modifiers
The variability of phenotypes associated with an SCN5A mutation can result from another genetic variant that coexists within gene. For example, two BrSassociated SCN5A variants T1620M and R1232W are known to cause minor changes in Na v 1.5 channel properties when they exist inde pendently. 26 When they coexist, however, the sodium channel T1620M/R1232W double mutant produces no current. 27 Indi viduals carrying either of the heterozygous lossoffunction mutations W156X or R225W do not have a clinical phenotype. 28 Compound heterozygosity for W156X and R225W mutations, however, leads to severe conduction disease, dilated cardiomyopathy, and death at a young age. 28 These examples demonstrate that the coexistence of a genetic variant within the SCN5A gene can affect the severity of the phenotype associated with another SCN5A mutation. Additionally, the SCN5A H558R polymorphism has been found to be a diseasemodifying genetic variant that can rescue gainoffunction 29 or lossoffunction 30 SCN5A mutations (Figure 4b ), providing a potential mecha nism to account for the variable penetrance that is often observed. Taken together, the presence of genetic modifiers within SCN5A might contribute to the phenotypic variabil ity, even between family members who share the same mutation.
Any stage in the lifecycle of the cardiac Na v 1.5 channel is a potential modification point to amplify, localize, or minimize a mutationmediated phenotype. The life cycle of cardiac Na v 1.5 includes gene transcrip tion, posttranscription RNA processing, translation (protein synthesis and assembly), posttranslational trafficking and modifica tions, and protein degradation ( Figure 5 ). 31, 32 I Na Modifiers such as transcription factors, microRNAs, and kinases regulate these pro cesses and result in functional changes of car diac Na v 1.5. These modifiers do not have established roles in modifying inherited Na v 1.5 channelopathies, but they can vary with age, sex, clinical state, and between regions of the heart. Conceivably, therefore, variability in these modifiers might con tribute to the overall phenotypic variability observed. Moreover, these modifiers are candidates to explain regional localization of Na v 1.5 mutation effects.
Transcriptional modifiers

Transcriptional regulation
Transcriptional dysregulation of SCN5A ( Figure 5 ) can lead to either upregulation or downregulation of Na v 1.5 mem brane expres sion and macroscopic I Na . This change in sodium current can enhance or mask the phenotype of a mutation. More over, regional differences in transcriptional regulation might explain how various areas of the heart and conduction system are most affected. Some transcriptional factors have essen tial roles in signalling normal SCN5A expres sion, dysregulation of which might dis rupt SCN5A expression and cause pheno typic variability. Tbox transcription fac tor TBX5 (TBX5) is essential for Na v 1.5 expression in the ventricular conduction system. 33 Removal of TBX5 causes a dra matic reduction in membrane expression of both Na v 1.5 and gap junction α5 protein (connexin40), leading to conduction velocity slowing, cardiac arrhythmias, and increased mortality in animal models. 33 Alterations in TBX5 expression might mod ulate I Na in the conduction system and con tribute to conductionspecific phenotypes. ARNTL, encoding a core molecular clock transcription factor, also has an impor tant role in SCN5A expression and cardiac arrhythmia susceptibility. Cardiomyocyte specific deletion of Arntl in mice causes slowed heart rate, prolonged electrocardio graphic RR and QRS intervals, and increa sed episodes of arrhythmia as a result of loss of Scn5a expression. 34 Alterations in Arntl might help to explain diurnal varia tions in arrhythmic risk in the presence of a p articular mutation.
The SCN5A promoter region con tains consensus binding sites for several transcription factors, such as nuclear factor NFκB (NFκB) and forkhead box protein O1 (FOXO1). When activated by angio tensin II or oxidative stress, NFκB and FOXO1 are upregulated and induce a significant decrease in Na v 1.5 expression and I Na . 35, 36 Interestingly, transforming growth factor β1 can counteract the effect of FOXO1 and increase the SCN5A mRNA level and I Na . 37 These data suggest that the phenotypic penetrance of a mutation might vary as a result of changes in these trans cription factors. Additionally, single nucleo tide poly morphisms in the promoter region of SCN5A have been shown to modulate the transcriptional activity of the gene, 38 and to affect the phenotypic severity in hetero zygous car riers of an SCN5A lossof function mutation (1936delC). 39 These data suggest that genetic variants in the SCN5A promoter region can contribute to the pheno typic variability of SCN5A mutations through r egulating SCN5A transcription.
mRNA processing and regulation
The phenotype of Na v 1.5 mutations can also be modified at the stage of mRNA pro cessing. Our group has shown that angio tensin II and hypoxia can regulate SCN5A mRNA splicing and generate truncated, nonfunctional sodium channels in human heart failure. 2 These abnormally spliced, truncated channels also show a dominant negative effect on the fulllength SCN5A mRNA transcript by activating eukaryotic translation initiation factor 2α kinase 3 (PERK; Figure 5 ). 40 Angiotensin II can be differentially regulated in local regions of the heart. In rats with type 1 diabetes mel litus, for example, the angiotensin II level is elevated in ventricular cells, but not in atrial cells. 41 Combining local regulation with induction of abnormal mRNA processing might contribute to a phenotype that varies according to clinical state.
MicroRNAs are endogenous, noncoding, small ribonucleic acids that are emerging as important regulators of gene expres sion by either restricting translation or inducing degradation of the target mRNA. Altered expression (mainly upregulation) of microRNAs has been widely reported to reduce the expression of cardiac ion channels in studies of cardiovascular dis eases. [42] [43] [44] In heart failure, upregulated microRNA125a/b was associated with suppression of Na v 1.5 protein expression and a reduction in I Na . 44 A stressinducibl e microRNA, microRNA195, which is upregu lated in cardiac hypertrophy and heart failure, 45 can downregulate SCN5A, leading to a reduction in I Na . 43 In myo cardial infarction, upregulation of the let7f microRNA and microRNA378 also causes a reduction in I Na . 44 Therefore, changes in microRNAs over time might contribute to phenotypic variability. Other microRNAs might have indi rect effects on the Na v 1.5 channel. For example, microRNA199a is down regulated after induction of ischaemia, leading to an upregulation of its target, hypoxia inducible factor 1α. This factor can activate RNAbinding protein 25, 46 and increase abnormal SCN5A mRNA splicing to gen erate truncated, nonfunctional sodium channels. 2, 40 In human atrial fibrillation and ventricular arrhythmia, microRNA1 is markedly decreased, which can induce upregulation of the K ir 2.1 potassium channel. 47 This channel conducts an inward potassium current (I K1 ) that controls the resting membrane potential (Figure 1 ). An increase in I K1 can lead to membrane hyper polarization, which can either amplify the reduction in I Na induced by an SCN5A lossoffunction mutation, or minimize the increase in I NaL induced by an SCN5A gain offunction mutation. In a canine tachy paced model of atrial fibrillation, the level of microRNA328 was increased, and led to a reduction in the voltagegated Ltype calcium channel current and a shortened atrial actionpotential duration. 48 These changes might combine with those of Na v 1.5 lossoffunction mutations to worsen arrhythmic risk.
Translational modifiers
At the translational level, many modi fiers regulate Na v 1.5 protein synthesis, folding, trafficking, and assembly with accessory subunits and interacting pro teins. For example, activated mitogen acti vate d protein kinases (MAPKs), such as p38MAPK and MAPK8, 49, 50 can affect trans lation of the Na v 1.5 channel and gap junction α1 protein (connexin43) and c ontribute to arrhythmia. [51] [52] [53] [54] Trafficking to cell membrane After SCN5A is translated to protein and assembled in the endoplasmic r eticulum, the channel is transited to the Golgi com plex, where Na v 1.5 channel trafficking begins. A Golgi vesicle containing the Na v 1.5 channel is then transported to the plasma membrane area. Modifiers such as cAMP dependent protein kinase (also known as protein kinase A; PKA) and protein kinase C (PKC) regulate channel traffick ing to the plasma membrane. For instance, PKC activation can decrease Na v 1.5 channel trafficking, whereas PKA can have the opposite effect. 55, 56 Therefore, a patient's clinical state might affect the p enetrance of a mutation.
Caveolae (small invaginations of the cell membrane) are potential Na v 1.5 modifiers, because colocalization of the Na v 1.5 protein and caveolin3 is observed in ventricular tissues. 57 Caveolae constitute a reservoir of I Na that can be modulated by opening or closing of the caveolar neck. 58 Caveolae also have a high density of signalling mol ecules, such as G proteins, PKA, PKC, and Src family tyrosine kinases. [59] [60] [61] A complex formed between caveolin3, Gsα protein, and PKA in caveolae modulates Na v 1.5 func tion. 61, 62 PKA and PKC regulate Na v 1.5 gating properties by phosphorylation. 63 A caveolin3 mutation results in a three fold increase in I NaL , which might enhance the penetrance of long QT syndrome type 3 induced by Na v 1.5 gainoffunction muta tions. 64 Any changes in these molecules will affect Na v 1.5 membrane availability and alter the phenotype of Na v 1.5 mutations.
Regulation of the channel complex
The Na v 1.5 α subunit interacts with acces sory proteins (β subunits and interacting proteins, reviewed previously 65 ) to form a macromolecular complex (Figure 2) . Mutations of these accessory proteins have been reported to cause BrS. For example, patients with BrS and mutations in the sodium channel β1 and β3 subunits show impaired Na v 1.5 channel function. 12, 66, 67 The expression level of the β4 subunit is reported to affect the severity of cardiac conduction disease in mice by modulating Na v 1.5 channel activation. 68 Na v 1.5 interacting proteins, such as ankyrin, Ran guanine nucleotide release factor (MOG1), and syntrophin, interact with the α and β subunits of the sodium channel. Mutations and misregulation of these proteins can disturb Na v 1.5 membrane expression and function. For example, a mutation in ankyrin2 causes long QT syn drome type 4, resulting from disruption of ankyrin2 interactions with Na v 1.5, the sodium/calcium exchanger, and inositol 1,4,5trisphosphate receptors. 69 Mutations in the MOG1 gene (RANGRF) are found in patients with BrS (E83D) 70 and atrial Age (years) Figure 4 | Examples of phenotypic variability in patients carrying an SCN5A mutation. a | Sex can affect the phenotype of long QT syndrome type 3. In these patients, men tend to have a longer QTc interval than women. 15 b | Genetic variants within or outside the gene can alter the phenotype of a SCN5A mutation. For example, the SCN5A H558R polymorphism has been shown to rescue the phenotype of P2006A and R282H mutations in SCN5A. 29, 30 c | Circadian changes in electrocardiogram patterns and the susceptibility to lethal ventricular fibrillation have been shown in Brugada syndrome. An electrocardiogram that is typical of Brugada syndrome (with STsegment elevation in the precordial leads) is more-frequently observed in the midnight-to-earlymorning period during sleep than during the day. fibrillation (E61X). 71 The A257G syntrophin mutation induces long QT syndrome type 3 owing to a gainoffunction modulation of Na v 1.5 gating properties. 72 Therefore, dif ferential regulation of the macromolecular complex is another potential modifier of the phenotype induced by a Na v 1.5 mutation.
Post-translational modifiers
PKA and PKC
The bestdefined posttranslational modi fiers of cardiac Na v 1.5 are PKA and PKC, which can modify channel expression and gating properties. Combined effects of these modifiers with the baseline genetic defect might explain phenotypes that vary with time, clinical state, and between regions of the heart.
Protein kinases regulate Na v 1.5 in fast and complex ways. For example, PKA and PKC regulate Na v 1.5 by affecting channel conductance, trafficking, and membrane expression. 1, 55, 56, 73 PKCs are a family of serine/threonine protein kinases with at least 15 isoforms in humans, with the PKCα, δ, and ε isoforms being mostintensively investigated in cardiomyocytes. 74 PKC decreases the cardiac I Na by channel redistri bution away from plasma membrane. 56 Additionally, PKCδ reduces I Na by inducing mitochondrial overproduction of reactive oxygen species (ROS) and decreasing the singlechannel conductance. 1, 63, 75, 76 These effects occur within minutes, without alter ing SCN5A mRNA abundance or channel membrane expression, suggesting that they are independent of effects on channel traf ficking. Therefore, PKC activation gener ally reduces I Na and might exacerbate the pheno type of SCN5A lossoffunction muta tions or mitigate the phenotype of SCN5A gainoffunction mutations. PKCε has not been found to regulate Na v 1.5 directly, but activation of PKCε has been reported to have a beneficial antiarrhythmic effect in a PKCε agonist transgenic mouse model of ischaemia-reperfusion injury. 77 This finding indicates that the state of PKCε activation might modulate the phenotypic variance of Na v 1.5 mutations.
PKA is a tetrameric serine/threonine kinase with broad specificity that is known to upregulate Na v 1.5 through changes in channel trafficking 55 and conductance. 63 Important PKA phosphorylation sites on human cardiac Na v 1.5 at Ser525, Ser528, Arg533, Arg534, and Arg535 have been identified. 55, 78, 79 Arg533-535 are impor tant for PKAdependent increases in I Na . 63 PKA can also upregulate Na v 1.5 through minimizing mitochondrial ROS produc tion. 1, 75 Furthermore, PKA activation of gap junction α1 protein (connexin43) stimulates gap junctional intercellular com munication and decreases the electrical distance over which Na v 1.5 mutations have their effects.
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ROS
Major sources of cardiac ROS include the mitochondrial electron transport chain, uncoupled nitric oxide synthase, NAD(P)H oxidase, cyclooxygenase, and xanthine dehydrogenase/oxidase. Enzymes such as superoxide dismutase, glutathione per oxidase, and catalase reduce ROS levels.
ROS elevation is a common feature shared by various cardiac diseases. 83, 84 Increasing evidence suggests that elevated levels of ROS affect the cardiac ion channels (such as Na v 1.5, K v 1.4, K v 4.2, K v 4.3, and Ca v 1.2), Ca 2+ handling proteins, and gapjunction proteins. 85 ROS can downregulate Na v 1.5 at the transcriptional level by reducing SCN5A expression, 35, 40 and at the posttranslational level by affecting channel phosphorylation and conductance. 63 For example, mito chondrial ROS can modify Na v 1.5 directly via an unknown mechanism that decreases I Na at the posttranslational level without changing channel membrane expression. 63 Mitochondrial ROS can also activate PKC, with SCN5A gene transcription in the nucleus, which can be regulated by transcription factors, such as FOXO1, NF-κB, and TBX5. The next steps are protein translation and assembly in the endoplasmic reticulum and Golgi apparatus. Appropriately folded Na v 1.5 protein is trafficked to the cell membrane, whereas misfolded protein (as a result of mutations and splicing variants) can activate the PERK pathway of the unfolded protein response to downregulate the SCN5A mRNA level. microRNAs also regulate the SCN5A mRNA level. Channel trafficking can be modulated by PKA, PKC, and caveolae. After being expressed on the cell membrane, NaChIPs join the α and β subunits to form a macromolecular complex, which can be regulated by PKA, PKC, oxidative stress (ROS), and metabolic states (NADH and NAD + ). Eventually, the channel will go through ubiquitin-mediated degradation, which can be regulated by NEDD4. Abbreviations: CAV3, caveolin-3; FOXO1, forkhead box protein O1; NaChIP, Na + -channel-interacting protein; NEDD4, E3 ubiquitin-protein ligase NEDD4; NF-κB, nuclear factor NF-κB; PERK, eukaryotic translation initiation factor 2α kinase 3; PKA, cAMP-dependent protein kinase (protein kinase A); PKC, protein kinase C; ROS, reactive oxygen species; TBX5, T-box transcription factor TBX5.
which can further downregulate channel activity by phosphorylation 63 or impairment of channel trafficking. 86 
Alterations in metabolism
Heart failure and cardiac injury from many causes are associated with altered metabo lism and downregulation of Na v 1.5. [87] [88] [89] [90] The level of NADH is known to oscillate during myocardial ischaemia, and mitochondrial injury is associated with increased NADH and ROS levels. 91, 92 An elevated level of NADH results in PKC activation, mitochon drial ROS overproduction, and decreased I Na . 1, 75 Many such alterations might be local ized to ischaemic regions of myocardium. By activating PKA, reducing mitochondrial ROS production, and enhancing I Na , NAD + antagonizes the reduction in I Na associ ated with a rise in the level of NADH. 1, 75 In an ex vivo study, NADH perfusion led to ventricular tachycardia induced by pro grammed electrical stimulation in wide type mouse hearts, whereas NAD + perfusion diminished the incidence of ventricular tachycardia in hearts from SCN5A +/-mice. 1 There fore, any alteration in cardiac meta bolism might alter the p henotype of Na v 1.5 mutations.
Degradation pathways
The last step of the Na v 1.5 channel lifecycle is degradation. A balance between synthesis and degradation of the channel determines the channel population available to gener ate currents. Ubiquitination of membrane proteins by ubiquitinprotein ligases is a common signal for protein internaliza tion and degradation. E3 ubiquitinprotein ligase NEDD4 (NEDD4) is a ubiquitin protein ligase that regulates the degrada tion of cardiac Na v 1.5, K v LQT1, and Ca v 1.2 channels. In Xenopus oocytes, Nedd4 sig nificantly reduces the membrane expression of these channels, and attenuates ion cur rents by 40-75%. 51, [93] [94] [95] [96] An inactive Nedd4 mutant can increase the Na v 1.5 density on the membrane and elevate I Na .
93 NEDD4 also regulates the degradation of neuronal sodium channels (Na v 1.2, Na v 1.3, Na v 1.7, and Na v 1.8), which are expressed in cardio myocytes and affect cardiac function (as dis cussed below). [95] [96] [97] NEDD4 can be regulated by PKA, MAPKs, serine/threonineprotein kinase Sgk, and 1433 proteins. [51] [52] [53] 98, 99 Therefore, any changes in NEDD4 and its modifiers might affect the membrane expression of cardiac ion channels, which will give rise to various phenotypes when combined with Na v 1.5 mutations.
Extrinsic modifiers
Other sodium channel isoforms In addition to cardiac Na v 1.5, the neuronal and skeletal isoforms of voltagegated sodium channels (Na v 1.1 to Na v 1.8) are also expressed in the heart. In adult mouse hearts, Na v 1.5 is responsible for 92% of I Na , whereas the other isoforms account for 8%.
100 Na v 1.1 and Na v 1.6 participate in pace making in the sinoatrial node, 101 and in excitation-contraction coupling.
102 Na v 1.6 has also been shown to act as a depolarizing reserve to ensure excitation. 102 Mutations in Na v 1.8, encoded by SCN10A, have been associated with prolonged cardiac conduc tion and an increased risk of heart block. 103 Na v 1.8 is mainly expressed in intracardiac neurons of the heart and has an important role in regulating the frequency of action potential firing in mice. 104 This channel also contributes to I NaL , and its inhibition might be antiarrhythmic. 105 An associa tion between common variants in SCN5A, SCN10A, and a transcriptional regulator gene HEY2 was reported in a genomewide association study of patients with BrS. 106 The cumulative effect of the three loci sig nificantly decreased cardiac conduction velocity and increased susceptibility to BrS. Differential regulation of these neuronal and skeletal isoforms of sodium chan nels might modulate the phenotype of any Na v 1.5 mutation.
Other cardiac ion channels Mutations in genes encoding channels other than Na v 1.5 are also associated with BrS and long QT syndrome type 3, which suggests that many different channels can be involved in generating one clinical phenotype. This idea implies that changes in these other ion channels can affect the phenotype of any Na v 1.5 mutation. For example, the SCN5A mutation D1275N has been shown to cause atrial standstill if this mutation is combined with poly morphisms in the atrialspecific gap junc tion α5 protein (connexin40). 107 The potassium current I to (conducted by K v 4.2 and K v 4.3) and I K1 (conducted by K ir 2.1) have been shown to modify I Na and affect the actionpotential duration and conduc tion velocity. I to counter acts the depolar izing currents during the early phase of the actionpotential plateau, resulting in an actionpotenti al notch (phase 1) and a 'spikeanddome' morpho logy (Figure 1) . In a canine heart model, increased I to at the early phase of action potential was found to cause conduction slowing. 108 When combined with I Na reduction, I to that is larger in sub epicardial than in subendocar dial myocytes can lead to loss of the action potential dome and early completion of repolar ization in the right ventricular sub epicardium, but not the subendocar dium. This situation can result in STsegment elevation being evident on the ECG in patients with BrS. Therefore, alterations or mutations of K v 4.3 and its accessory proteins could amplify early after depolari zations or mitigate early r epolarization in BrS. I K1 controls the resting membrane poten tial, which determines voltagegated Na v 1.5 availability. I K1 -I Na interactions have been shown to involve reciprocal modulation of their respective channel expressions within a macromolecular complex. 109 An increase in I K1 expression can lead to membrane hyperpolarization, which can either amplify a reduction in I Na induced by SCN5A lossof function mutations, or minimize an increase in I NaL induced by SCN5A gainoffunction mutations.
Genetic and genomic background
Genetic background can contribute to the variable phenotypes observed with SCN5A mutations. A study in families with BrS carry ing SCN5A mutations suggested that the presence of the Brugada phenotype is determined not only by SCN5A mutation, but also by the genetic background of an individual. 110 The SCN5A 1798insD/+ muta tion has been found to generate a more severe phenotype of conduction slowing in mice with a 129P2 genetic background than in those with a FVB/N background. 68 A genomewide association study in patients with BrS showed that polymorphisms in SCN10A and HEY2 can have a large effect on the phenotype of BrS. 106 Therefore, multi ple genetic mutations in unrelated genes can act to lower I Na and cause BrS, which high lights the importance of considering genetic and genomic modifiers when undertaking g enotype-phenotype correlations. 66, 67, 111, 112 
Conclusions
Mutations in the cardiac Na v 1.5 can result in various clinical syndromes. Some of this phenotypic variability can be explained by the direct effect of the mutation on channel properties and biophysics. Conversely, mani festation of the mutation in a particu lar region or chamber of the heart, circadian variation, agedependent arrhythmic epi sodes, incomplete penetrance in families, and variations according to clinical state within an affected individual are difficult to explain. We propose that this variability might be the result of secondary modifiers of the Na v 1.5 channel. We have divided these modifiers into those within the SCN5A gene, those intrinsic to the lifecycle of Na v 1.5, and those extrinsic to Na v 1.5, which can modify overall electrical function. However, much of the evidence for modi fiers of Na v 1.5 expression and function has been derived from the literature on heart failure. Further experimental evidence will be required to support and generalize this 'secondhit' hypothesis of phenotypic vari ability to the field of arrhythmia s yndromes associated with SCN5A mutations. Na v 1.5 channel modifiers might conceiv ably alleviate or aggravate the phenotype of an SCN5A mutation, depending on their effect on the sodium current or the overall balance of currents. Localized modifier changes might explain regional expression of mutation effects. Changes in modifiers might also explain why some conduction disease phenotypes progress and others do not. Variations in modifiers could explain why ECG manifestations and arrhythmic risk varies with time of day and with age. These considerations might also explain why less phenotypic variability exists in gainoffunction mutations than in lossof function mutations, because fewer modi fiers exist that affect only inactivation than affect overall channel current. Nevertheless, the net effect of a gainoffunction muta tion can be modulated by the total number of available channels, which might explain the variable penetrance of a phenotype with time or between regions of the heart. In summary, considering these modifiers might improve genotype-phenotype cor relation and riskprediction algor ithms. More over, targeting modifiers might prove to be an effective strategy to prevent diseases associated with Na v 1.5 mutations.
